BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35131871)

  • 41. Loss of Pax5 Exploits Sca1-BCR-ABL
    Martín-Lorenzo A; Auer F; Chan LN; García-Ramírez I; González-Herrero I; Rodríguez-Hernández G; Bartenhagen C; Dugas M; Gombert M; Ginzel S; Blanco O; Orfao A; Alonso-López D; Rivas JL; García-Cenador MB; García-Criado FJ; Müschen M; Sánchez-García I; Borkhardt A; Vicente-Dueñas C; Hauer J
    Cancer Res; 2018 May; 78(10):2669-2679. PubMed ID: 29490943
    [TBL] [Abstract][Full Text] [Related]  

  • 42. JAKs to STATs: A tantalizing therapeutic target in acute myeloid leukemia.
    Venugopal S; Bar-Natan M; Mascarenhas JO
    Blood Rev; 2020 Mar; 40():100634. PubMed ID: 31677846
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia.
    Suryani S; Bracken LS; Harvey RC; Sia KC; Carol H; Chen IM; Evans K; Dietrich PA; Roberts KG; Kurmasheva RT; Billups CA; Mullighan CG; Willman CL; Loh ML; Hunger SP; Houghton PJ; Smith MA; Lock RB
    Mol Cancer Ther; 2015 Feb; 14(2):364-74. PubMed ID: 25504635
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Frequency and prognostic impact of PAX5 p.P80R in pediatric acute lymphoblastic leukemia patients treated on an AIEOP-BFM acute lymphoblastic leukemia protocol.
    Jung M; Schieck M; Hofmann W; Tauscher M; Lentes J; Bergmann A; Stelter M; Möricke A; Alten J; Schlegelberger B; Schrappe M; Zimmermann M; Stanulla M; Cario G; Steinemann D
    Genes Chromosomes Cancer; 2020 Nov; 59(11):667-671. PubMed ID: 32592278
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Metabolic gatekeeper function of B-lymphoid transcription factors.
    Chan LN; Chen Z; Braas D; Lee JW; Xiao G; Geng H; Cosgun KN; Hurtz C; Shojaee S; Cazzaniga V; Schjerven H; Ernst T; Hochhaus A; Kornblau SM; Konopleva M; Pufall MA; Cazzaniga G; Liu GJ; Milne TA; Koeffler HP; Ross TS; Sánchez-García I; Borkhardt A; Yamamoto KR; Dickins RA; Graeber TG; Müschen M
    Nature; 2017 Feb; 542(7642):479-483. PubMed ID: 28192788
    [TBL] [Abstract][Full Text] [Related]  

  • 46. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
    Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
    Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.
    Gu Z; Churchman ML; Roberts KG; Moore I; Zhou X; Nakitandwe J; Hagiwara K; Pelletier S; Gingras S; Berns H; Payne-Turner D; Hill A; Iacobucci I; Shi L; Pounds S; Cheng C; Pei D; Qu C; Newman S; Devidas M; Dai Y; Reshmi SC; Gastier-Foster J; Raetz EA; Borowitz MJ; Wood BL; Carroll WL; Zweidler-McKay PA; Rabin KR; Mattano LA; Maloney KW; Rambaldi A; Spinelli O; Radich JP; Minden MD; Rowe JM; Luger S; Litzow MR; Tallman MS; Racevskis J; Zhang Y; Bhatia R; Kohlschmidt J; Mrózek K; Bloomfield CD; Stock W; Kornblau S; Kantarjian HM; Konopleva M; Evans WE; Jeha S; Pui CH; Yang J; Paietta E; Downing JR; Relling MV; Zhang J; Loh ML; Hunger SP; Mullighan CG
    Nat Genet; 2019 Feb; 51(2):296-307. PubMed ID: 30643249
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells.
    Fazio G; Palmi C; Rolink A; Biondi A; Cazzaniga G
    Cancer Res; 2008 Jan; 68(1):181-9. PubMed ID: 18172310
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Stem cell-like reprogramming is required for leukemia-initiating activity in B-ALL.
    Fregona V; Bayet M; Bouttier M; Largeaud L; Hamelle C; Jamrog LA; Prade N; Lagarde S; Hebrard S; Luquet I; Mansat-De Mas V; Nolla M; Pasquet M; Didier C; Khamlichi AA; Broccardo C; Delabesse É; Mancini SJC; Gerby B
    J Exp Med; 2024 Jan; 221(1):. PubMed ID: 37930337
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential.
    Tzeng HT; Chyuan IT; Lai JH
    Biochem Pharmacol; 2021 Nov; 193():114760. PubMed ID: 34492272
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oncogenic role of Pax5 in the T-lymphoid lineage upon ectopic expression from the immunoglobulin heavy-chain locus.
    Souabni A; Jochum W; Busslinger M
    Blood; 2007 Jan; 109(1):281-9. PubMed ID: 16968900
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia.
    Zhang M; Mathews Griner LA; Ju W; Duveau DY; Guha R; Petrus MN; Wen B; Maeda M; Shinn P; Ferrer M; Conlon KD; Bamford RN; O'Shea JJ; Thomas CJ; Waldmann TA
    Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12480-5. PubMed ID: 26396258
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.
    Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN
    J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Germline PAX5 mutations and B cell leukemia.
    Hyde RK; Liu PP
    Nat Genet; 2013 Oct; 45(10):1104-5. PubMed ID: 24071841
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ph-like acute lymphoblastic leukemia with a novel PAX5-KIDINS220 fusion transcript.
    Sakamoto K; Imamura T; Kanayama T; Yano M; Asai D; Deguchi T; Hashii Y; Tanizawa A; Ohshima Y; Kiyokawa N; Horibe K; Sato A
    Genes Chromosomes Cancer; 2017 Apr; 56(4):278-284. PubMed ID: 27870151
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia.
    Tavakoli Shirazi P; Eadie LN; Page EC; Heatley SL; Bruning JB; White DL
    Cancer Lett; 2021 Aug; 512():28-37. PubMed ID: 33971281
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of Jak/STAT signaling reduces the activation of pancreatic stellate cells in vitro and limits caerulein-induced chronic pancreatitis in vivo.
    Komar HM; Serpa G; Kerscher C; Schwoegl E; Mace TA; Jin M; Yang MC; Chen CS; Bloomston M; Ostrowski MC; Hart PA; Conwell DL; Lesinski GB
    Sci Rep; 2017 May; 7(1):1787. PubMed ID: 28496202
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The reduced and altered activities of PAX5 are linked to the protein-protein interaction motif (coiled-coil domain) of the PAX5-PML fusion protein in t(9;15)-associated acute lymphocytic leukemia.
    Qiu JJ; Chu H; Lu X; Jiang X; Dong S
    Oncogene; 2011 Feb; 30(8):967-77. PubMed ID: 20972455
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Human diseases caused by impaired signal transducer and activator of transcription and Janus kinase signaling.
    Chaimowitz NS; Forbes LR
    Curr Opin Pediatr; 2019 Dec; 31(6):843-850. PubMed ID: 31693596
    [TBL] [Abstract][Full Text] [Related]  

  • 60. JAK/STAT signaling pathway-mediated immune response in silkworm (Bombyx mori) challenged by Beauveria bassiana.
    Geng T; Lv DD; Huang YX; Hou CX; Qin GX; Guo XJ
    Gene; 2016 Dec; 595(1):69-76. PubMed ID: 27693371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.